GlaxoSmithKline plc (GSKN) — Capital Reinvestment Ratio
GlaxoSmithKline plc (GSKN) has a Capital Reinvestment Ratio of 0.40x as of September 2025, meaning it reinvests 0% of its operating cash flow (MX$2.22 Billion) in capital expenditures (MX$879.00 Million). See GSKN net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GlaxoSmithKline plc Capital Reinvestment Ratio (2013–2024)
This chart tracks GlaxoSmithKline plc's Capital Reinvestment Ratio across 12 annual periods. Check GSKN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for GlaxoSmithKline plc (2013–2024)
Year-by-year Capital Reinvestment Ratio for GlaxoSmithKline plc from 2013 to 2024. For live market cap and broader valuation context, see market value of GlaxoSmithKline plc.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | MX$6.55 Billion | MX$2.98 Billion | ▲ +7.8% |
| 2023 | 0.42x | MX$5.48 Billion | MX$2.31 Billion | ▲ +173.4% |
| 2022 | 0.15x | MX$7.40 Billion | MX$1.14 Billion | ▲ +29.2% |
| 2021 | 0.12x | MX$7.95 Billion | MX$950.00 Million | ▲ +2.0% |
| 2020 | 0.12x | MX$8.44 Billion | MX$989.00 Million | ▼ -25.7% |
| 2019 | 0.16x | MX$8.02 Billion | MX$1.26 Billion | ▼ -1.2% |
| 2018 | 0.16x | MX$8.42 Billion | MX$1.34 Billion | ▼ -28.5% |
| 2017 | 0.22x | MX$6.92 Billion | MX$1.54 Billion | ▼ -38.3% |
| 2016 | 0.36x | MX$6.50 Billion | MX$2.35 Billion | ▼ -32.6% |
| 2015 | 0.54x | MX$2.57 Billion | MX$1.38 Billion | ▲ +134.0% |
| 2014 | 0.23x | MX$5.18 Billion | MX$1.19 Billion | ▲ +39.5% |
| 2013 | 0.16x | MX$7.22 Billion | MX$1.19 Billion | — |